期刊
ALZHEIMERS & DEMENTIA
卷 13, 期 5, 页码 499-509出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2016.08.010
关键词
Alzheimer's disease; CSF; Biomarkers; Longitudinal; MRI; Amyloid; Tau
资金
- Carlos III Institute of Health, Spain [PI11/02425, PI14/ 01126, PI10/1878, PI13/01532, PI11/03035, PI14/1561]
- Generalitat de Catalunya [2014SGR-0235]
- CIBERNED program
- Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, Una manera de hacer Europa
- Marato TV3 grant [20141210]
- Spanish government FPU (Formacion del Profesorado Universitario) [AP2012-0400]
- Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
- DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- Canadian Institutes of Health Research
Introduction: Brain structural changes in preclinical Alzheimer's disease (AD) are poorly understood. Methods: We compared the changes in cortical thickness in the ADNI cohort during a 2-year follow-up between the NIA-AA preclinical AD stages defined by cerebrospinal fluid (CSF) biomarker levels. We also analyzed the correlation between baseline CSF biomarkers and cortical atrophy rates. Results: At follow-up, stage 1 subjects showed reduced atrophy rates in medial frontal areas and precuneus compared to stage 0 subjects, whereas stage 2/3 subjects presented accelerated atrophy in medial temporal structures. Low CSF A beta(1-42) levels were associated with reduced atrophy rates in subjects with normal tau levels and high CSF tau levels with accelerated atrophy only in subjects with low A beta(1-42) levels. Discussion: Our longitudinal data confirm a biphasic trajectory of changes in brain structure in preclinical AD. These have implications in AD trials, both in patient selection and the use of MRI as a surrogate marker of efficacy. (C) 2016 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据